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Abstract
Background: Health utilities are preference-based measures for health states which are typically used in economic
analyses to estimate quality-adjusted life years. Our aim is to report the standard SF-6D health utility scores in
Japanese patients with hepatitis C virus (HCV) during treatment with different regimens.
Methods: Japanese patients were enrolled in clinical trials of sofosbuvir (SOF) used in combination with or without
ledipasvir (LDV) and/or ribavirin (RBV). The SF-6D health utility scores were calculated at multiple time points from
the SF-36 instrument.
Results: Four hundred ninety-four patients with HCV (genotype 1 and 2) were enrolled: 19% with cirrhosis, 48%
with a prior history of anti-HCV treatment. Of those, 153 received SOF + RBV, 170 received LDV/SOF + RBV, 171
received LDV/SOF for 12 weeks; the SVR rates were: 97, 98 and 100%, respectively. Patients treated with the three
regimens had similar SF-6D scores before treatment (p = 0.87): 76.1 ± 11.5. During treatment with RBV containing
regimen, patients experienced a decrement in their health utility scores to 74.3 ± 12.5 by the end of treatment
(p = 0.03), while patients treated with RBV-free LDV/SOF had their SF-6D scores improved to 79.2 ± 12.8 after
12 weeks of treatment (p = 0.0004). At post-treatment week 12, in patients who achieved SVR-12, the SF-6D scores
were similar between the treatment regimens (p = 0.36), and an average improvement of +1.4 points from baseline
(p = 0.01) was noted. In multivariate analysis, the use of RBV was independently associated with lower utility score
during treatment (beta = 4.7 ± 1.6, p < 0.0001).
Conclusion: Health utilities are lower in Japanese HCV patients and tend to improve after clearance of infection.
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Background
Hepatitis C infection (HCV) causes a systemic disease
with both hepatic and extrahepatic manifestations [1, 2],
and also affects patient-reported outcomes (PROs) by
causing significant fatigue, a decrease patients’ physical
and mental functioning (measured by health-related qual-
ity of life (HRQL) survey tools) and negatively affecting
worker productivity [2–6].
Introduction of the new all-oral interferon-free direct-
acting antiviral regimens (DAAs) has changed the land-
scape of treatment and its associated outcomes. Presently,
the remarkably high cure rates of these new therapies has
allowed attention to shift to investigating the impact of
treatment on PROs. In fact, recent studies have reported
that PROs have been significantly positively affected [6–9];
in particular, in some patient groups, these positive
changes occurred within 2 weeks of treatment [10].
Although interferon (IFN)-based regimens have been the
historical regimens for treatment of HCV in Japan, the
newer regimens free of IFN were recently approved and are
now widely used in Japan [11–14]. Despite the successful
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outcomes of the new DAAs, the cost of treatment has
caused great concern and discussion about who should
receive treatment and during what stage of disease. As a
result, a number of cost-effectiveness studies have been
published highlighting that treatment with the DAAs is
cost-effective for both the patient and the society [15–18].
However, the majority of these studies have been carried
out in the Western and European countries leaving a gap of
knowledge of how these results would transfer to the Asian
population, especially given that HCV is the most common
cause of chronic liver disease in Japan leading to high rates
of cirrhosis and hepatocellular carcinoma [19, 20]. So far, to
the best of our knowledge, there are no systematically
collected health utility data on the impact of treatment to
determine cost-effectiveness and QALYs gained as a result
of using the new DAA regimens within the Japanese popula-
tion. Therefore, the purpose of this study was to estimate
health utility scores for the Japanese population so that cost-
effectiveness studies can be carried out for this population.
Methods
We used the exploratory endpoints data collected in two
multicenter phase 3 clinical trials of sofosbuvir-based regi-
mens for treatment of chronic hepatitis C (GS-US-337-0113
and GS-US-334-0118). These trials were conducted in Japan
in 2013–2015 [12, 13]. In both trials, otherwise healthy (i.e.,
without current or prior history of any clinically-significant
illness other than HCV) treatment-naïve or treatment-
experienced HCV patients of both genders with or without
compensated cirrhosis were enrolled to receive sofosbuvir
(400 mg) in combination with ribavirin (weight-based 1000/
1200 mg) for HCV genotype 2, or a fixed-dose combination
of ledipasvir and sofosbuvir (90 mg/400 mg) with or without
ribavirin for HCV genotype 1. All studied treatment regi-
mens lasted for 12 weeks. The details of the study design for
the original trials, including inclusion and exclusion criteria,
and the safety and efficacy results have been published [12,
13]. For this study, similarly to our prior report for that co-
hort [21], using extensive medical history collected at
screening for all enrolled participants, we identified patients
with pre-treatment history of depression or mood disorders,
anxiety or panic disorders, insomnia or sleep disorders, and
type 2 diabetes or hyperglycemia, and then tested these
conditions as independent predictors of the utility scores as
described below.
Patients with detectable HCV RNA at post-treatment
week 4 were not followed-up at subsequent follow-up
visits. Patients were considered to have achieved sustained
virologic response (SVR-12) if they had undetectable HCV
RNA at post-treatment week 12.
Health utility scores
In general, a health utility score is a single summary meas-
ure of patients’ preference for a certain state of health which
is calculated by applying a preference-based weight to each
patient’s health status; those preference-based weights are
typically calculated in an a priori development or validation
study for a specific health utility metric. There exist a num-
ber of instruments designed specifically for calculation of
health utility scores (HUI-2, EQ-5D, etc.) Notably, since
most popular HRQL instruments, including SF-36, do not
include any patients’ preferences to their scoring algorithms,
the HRQL scores cannot be directly used in the role of util-
ity scores. Thus, when specific health utility instruments are
not available, regression-based methods for estimating
health utility scores from the HRQL scores are typically
used. One of such widely used approximations of health
utility scores is SF-6D metric which can be calculated from
SF-36; a number of parametric and non-parametric algo-
rithms have been published and validated [22–24].
In this study, patients completed the Short Form-36
version 2 (SF-36v2) questionnaire in their native lan-
guage at baseline, during, and after treatment; we used
the SF-36 data to derive participants’ SF-6D health util-
ity scores by a Bayesian non-parametric algorithm [22].
Also, for the purpose of presentation, the SF-6D scores
were transformed from a conventional 0–1 to a 0–100
scale by multiplying the scores by 100.
Statistical analysis
The baseline health utility scores of Japanese patients
were summarized and compared across the treatment
regimens using the Kruskal-Wallis non-parametric test.
The changes (decrements or improvements) in the util-
ity scores from patients’ own baseline levels were calcu-
lated for each patient at each study time point, and the
median changes were compared to zero (the null hy-
pothesis of no change) by a sign rank test. Only p-values
of 0.05 or less were considered statistically significant.
Also, in Japanese patients, independent predictors of
their SF-6D utility scores were assessed using a repeated
measures mixed linear model. The list of potential fixed-
effect predictors initially included in the regression
model was as follows: age (≤60 vs. ≥60), gender, obesity
(defined as BMI ≥25), history of insomnia, psychiatric
disorders and type 2 diabetes, hemoglobin, cirrhosis, and
history of prior anti-HCV treatment. Only statistically
significant fixed effect predictors were left in the model
after a bidirectional stepwise selection; the significance
thresholds were 0.2 for entry, 0.05 for stay.
All analyses were run in SAS 9.3 (SAS Institute, Cary,
NC). Both studies (334-0118 and 337-0113) were separ-
ately approved by each site’s Institutional Review Board.
Results
There were 153 Japanese patients enrolled in GS-US-
334-0118 to receive 12 weeks of SOF + RBV (SVR 97%),
and 341 patients enrolled in GS-US-337-0113 to receive
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12 weeks of LDV/SOF with or without RBV (170 re-
ceived LDV/SOF ± RBV with SVR = 98%, and 171 re-
ceived LDV/SOF with SVR = 100%). The demographics
and baseline clinical presentation of the study cohort
have been reported [21]. Briefly, the cohort was 58.6 ±
9.7 years of age, 43% male, 52% treatment-naïve and
19% cirrhotic. Patients receiving different SOF-based
regimens were similar in most of their characteristics ex-
cept for HCV genotype and the rate of cirrhosis: those
with HCV genotype 2 who were exclusively enrolled to
receive SOF + RBV had a substantially lower cirrhosis
prevalence (11% vs. 22%, p < 0.01) (Table 1).
The baseline SF-6D utility scores were identical in all
three treatment regimen groups (p = 0.87) (Table 2).
When compared between subgroups of the entire co-
hort, significant differences in the baseline utility scores
were found between men and women (78.4 ± 11.8 vs.
74.4 ± 11.0, p < 0.0001) and patients with and without
history of sleep disorders (71.9 ± 10.4 vs. 76.8 ± 11.5, p =
0.0008), but no significant difference was found between
treatment-naïve and treatment-experienced patients (p =
0.41). Although there was a trend for those with or with-
out cirrhosis, it did not reach statistical significance
(74.4 ± 11.6 vs. 76.5 ± 11.4, p = 0.116). Finally, SF-D
scores for patients older than 60 and younger than 60
were 74.5 ± 11.5 vs. 77.9 ± 11.2 (p = 0.0003).
During treatment with RBV-containing regimens, a
moderate decline in the utility scores was noted in Japa-
nese patients receiving SOF + RBV (p = 0.035) (Table 2,
Fig. 1). This decline, however, was completely resolved
by post-treatment week 4. On the other hand, no on-
treatment or post-SVR improvements in the utility
scores were noted in patients treated with SOF + RBV or
LDV/SOF + RBV (all p > 0.05).
In contrast, patients treated with RBV-free LDV/SOF
experienced a rapid improvement in their average health
utility scores soon after treatment initiation: p = 0.10 by
treatment week 4, p < 0.05 after treatment week 8. These
improvements also persisted after treatment cessation
(Table 2, Fig. 1). Overall, at post-treatment week 12, a
positive change from the baseline level was noted in
50.6% of all Japanese patients with HCV.
In a mixed linear model, independent predictors of
lower SF-6D scores in Japanese patients included older
age, female gender, and having a history of sleep disor-
ders (Table 3). Interacted with time, receiving a RBV-
containing treatment regimen was also independently
associated with lower utility scores in Japanese HCV pa-
tients: beta = −5.3 for LDV/SOF + RBV, −4.1 for SOF +
RBV (both p < 0.005).
Discussion
This is the first study to report health utilities of
Japanese HCV patients during treatment with DAAs.
Notably, the most recent cost-utility studies aimed to
model DAA-based treatment in Japanese HCV popula-
tion relied on utility scores collected from American and
European patients [25, 26]. It is reasonable to believe,
however, that preference-based health utility metrics, be-
ing patient-reported outcomes per se, could be substan-
tially affected by patients’ ethnicity, as suggested in a
number of prior studies of both HCV and other clinical
populations [27–31].
In this study, we showed that, at baseline, female Japanese
patients with HCV, patients with history of sleep disorders,
Table 1 Baseline clinico-demographic parameters and health utility scores in GS-US-337-0113 and GS-US-334-0118
LDV/SOF LDV/SOF + RBV SOF + RBV P All
N 171 170 153 494
Age, years 59.7 ± 9.2 59.2 ± 9.5 56.8 ± 10.1 0.0310 58.6 ± 9.7
Male 69 (40.4%) 73 (42.9%) 70 (45.8%) 0.62 212 (42.9%)
HCV genotype 1 171 (100.0%) 170 (100.0%) 0 (0.0%) <0.0001 341 (69.0%)
HCV genotype 2 0 (0.0%) 0 (0.0%) 153 (100.0%) 153 (31.0%)
Treatment-naïve 83 (48.5%) 83 (48.8%) 90 (58.8%) 0.11 256 (51.8%)
Cirrhosis 41 (24.0%) 35 (20.6%) 17 (11.1%) 0.0097 93 (18.8%)
History of anxiety 8 (4.7%) 4 (2.4%) 3 (2.0%) 0.30 15 (3.0%)
History of depression 3 (1.8%) 7 (4.1%) 5 (3.3%) 0.44 15 (3.0%)
History of insomnia 24 (14.0%) 21 (12.4%) 21 (13.7%) 0.89 66 (13.4%)
Table 2 The SF-6D health utility scores (0-100) of Japanese
patients with CH-C before, during and after treatment
LDV/SOF LDV/SOF
+ RBV
SOF + RBV p
Baseline 76.4 ± 12.4 75.9 ± 10.3 76.1 ± 11.8 0.87
Treatment week 4 78.3 ± 12.1 75.5 ± 12.4 76.2 ± 13.0 0.10
Treatment week 8 78.8 ± 12.6* 74.4 ± 11.4 75.5 ± 13.6 0.0023
Treatment week 12 79.2 ± 12.8* 74.3 ± 12.5* 75.7 ± 13.1 0.0012
Post-treatment week 4 78.4 ± 13.1* 76.1 ± 13.3 77.4 ± 13.5 0.28
Post-treatment week 12 78.6 ± 13.0* 76.7 ± 12.3 77.1 ± 14.0 0.36
*p < 0.05 when compared to the baseline level
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and older HCV patients all have more impairment of health
utilities as determined by their SF-6D scores (Table 3).
These findings are consistent with what has been already
reported for other worldwide HCV populations, anti-HCV
regimens, and outcomes (such as HRQL and activity
scores, fatigue, work productivity) [6–9, 32, 33]. They are
also important because a large number of Japanese patients
with HCV are older, and older patients seem to have a
moderately impaired effect of DAAs on improvement of
their HRQL [34]. This may also influence cost-effectiveness
of the new regimens in older Japanese patients with HCV
which, however, has to be studied separately.
Our study also showed that RBV-containing regimens
(SOF ± RBV or LDV/SOF ± RBV) caused a mild decre-
ment in the SF-6D scores during treatment; however,
scores soon recovered after treatment discontinuation.
In contrast, the IFN- and RBV-free regimen (LDV/SOF)
was found to lead to an improvement of health utilities
during treatment of Japanese patients with HCV infec-
tion. In fact, in our multivariate analysis (Table 3), LDV/
SOF was independently associated with higher health
utility scores. Furthermore, our analysis showed that
LDV/SOF is the only regimen that is associated with
improvement of health utility scores post-SVR-12. This
is again consistent with prior studies of utilities and
other PROs in this and other populations [8, 9, 21, 33].
The study limitations include the use of the SF-6D
health utility measurement which, although is widely used
in cost-effectiveness studies, is still a derived score rather
than a prospectively measured preference-based metric.
Another limitation of our study was the small sample size
of cirrhotic patients with HCV, especially those with ad-
vanced cirrhosis. Obtaining this data will be important to
assess the impact of HCV infection for the entire
spectrum of Japanese patients with chronic hepatitis C.
Conclusions
In summary, we report the first health utility data for
Japanese patients with HCV who were treated with the
interferon-free regimens. These data can be used by
health policy makers to assess the cost effectiveness of
these highly effective new anti-HCV regimens in Japan.
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Fig. 1 SF-6D health utility scores in Japanese CH-C patients before,
during and after treatment with different treatment regimens
Table 3 Independent predictors of health utilities in Japanese
patients (p < 0.05 only)
Predictor Beta Std. Err. p
Age≥ 60 years −4.18 0.94 <0.0001
Male gender 3.15 0.94 <0.0001
Insomnia −6.10 1.38 <0.0001
Treatment regimen (interacted with time – end of treatment only)
LDV/SOF reference
LDV/SOF + RBV −5.33 1.32 <0.0001
SOF + RBV −4.06 1.36 0.0030
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